UCB - PE Price to Earnings


UCB reported 29.7 in PE Price to Earnings for its fiscal semester ending in December of 2025.





Pe Change Date
Alcon AG 36.42 1.77 Mar/2026
Almirall 79.43 0.3 Dec/2025
Amarin 91.05 88.3 Jun/2023
argenx SE 32.12 10.9 Mar/2026
AstraZeneca 29.59 2.3 Mar/2026
Bayer 3.4 8.75 Mar/2026
Genmab 17.14 4.39 Dec/2025
GlaxoSmithKline 14.87 3.72 Mar/2026
GRIFOLS 10.98 5.83 Mar/2026
Hikma Pharmaceutical 10.43 3.72 Dec/2025
Lakefront Biotherapeutics 2.54 0.6 Mar/2026
Lonza 34.34 2.58 Dec/2025
Merck 12.74 7.82 Mar/2026
Novartis 20.17 2.32 Mar/2026
Orion 18.52 10.02 Mar/2026
Recordati 17.66 7.44 Mar/2026
Roche Holding 16.09 3.51 Dec/2025
Sanofi 11.84 0.14 Mar/2026
UCB 29.7 5.52 Dec/2025
Unibail Rodamco 10.36 0.43 Dec/2025